Scarica l'app Stockscreener
26.88
10.15%
-3.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$30.04
Aprire:
$29.3
Volume 24 ore:
334.29K
Relative Volume:
0.31
Capitalizzazione di mercato:
$1.48B
Reddito:
$199.89M
Utile/perdita netta:
$52.48M
Rapporto P/E:
31.62
EPS:
0.85
Flusso di cassa netto:
$61.15M
1 W Prestazione:
-18.21%
1M Prestazione:
+5.59%
6M Prestazione:
+180.27%
1 anno Prestazione:
+109.88%
Intervallo 1D:
$26.89
$29.44
Intervallo di 1 settimana:
$26.93
$33.13
Portata 52W:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
26.95 | 1.65B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.65 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.69 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.38 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Using portfolio simulators with Stoke Therapeutics Inc. includedJuly 2025 Institutional & Safe Capital Investment Plans - newser.com
What technical models suggest about Stoke Therapeutics Inc.’s comebackJuly 2025 Highlights & Risk Managed Investment Strategies - newser.com
Will Stoke Therapeutics Inc. stock maintain momentum in 2025Market Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com
Live market analysis of Stoke Therapeutics Inc.Insider Selling & Weekly Return Optimization Plans - newser.com
Does Stoke Therapeutics Inc. show high probability of rebound2025 Volume Leaders & Technical Analysis for Trade Confirmation - newser.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stoke Therapeutics Shares Plunge Following Clinical Trial Data Release - AD HOC NEWS
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.3%Should You Sell? - MarketBeat
Is Stoke Therapeutics Inc. stock a good choice for value investorsTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
What insider trading reveals about Stoke Therapeutics Inc. stockTrade Risk Assessment & Daily Technical Forecast Reports - newser.com
Stoke Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Exit strategy if you’re trapped in Stoke Therapeutics Inc.July 2025 Macro Moves & Weekly High Return Opportunities - newser.com
Stoke Therapeutics, Inc. (STOK) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Total debt per share of Stoke Therapeutics, Inc. – BER:0GT - TradingView
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates - Business Wire
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - Nasdaq
Stoke Therapeutics (STOK) Projected to Post Earnings on Tuesday - MarketBeat
Will Stoke Therapeutics Inc. stock maintain dividend yieldExit Point & AI Forecast for Swing Trade Picks - Fundação Cultural do Pará
Why Stoke Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Stock Market Timing Techniques - fcp.pa.gov.br
Take Profit: Is Stoke Therapeutics Inc. stock a good choice for value investorsTrade Risk Summary & Target Return Focused Stock Picks - fcp.pa.gov.br
Dravet Syndrome Pipeline 2025: Key Developments, Emerging - openPR.com
How Stoke Therapeutics Inc. stock trades before earningsDividend Hike & Step-by-Step Swing Trade Plans - Fundação Cultural do Pará
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):